184:
intervention may be as much as 5% less effective than the control would have assay sensitivity. On the other hand, with this same data, a noninferiority trial designed to rule out that the test intervention may be as much as 15% less effective than the control may not have assay sensitivity, since this trial would not ensure that the test intervention is any more effective than a placebo given that the effect ruled out is larger than the effect of the control compared to placebo. The choice of the margin is sometimes problematic in non-inferiority trials. Given investigators desire to choose larger margins to decrease the sample size needed to perform a trial, the chosen margin is sometimes larger than the effect size of the control compared to placebo. In addition, a valid noninferiority trial is not possible in situations in which there is a lack of data demonstrating a reliable and reproducible effect of the control compared to placebo.
188:
way, non-inferiority trials have a feature in common with external (historically) controlled trials. This also means that non-inferiority trials are subject to some of the same biases as historically controlled trials; that is, the effect of a drug in a past trial may not be the same in a current trial given changes in medical practice, differences in disease definitions or changes in the natural history of a disease, differences in outcome timing and definitions, usage of concomitant medications, etc.
22:
187:
In addition to choosing a margin based upon credible past evidence, to have assay sensitivity, the planned non-inferiority trial must be designed in a way similar to the past trials which demonstrated the effectiveness of the control compared to placebo, the so-called "constancy assumption". In this
178:
for a non-inferiority trial may depend upon the chosen margin of inferiority ruled out by the trial, and the design of the planned non-inferiority trial. The chosen margin of inferiority in a non-inferiority trial cannot be larger than the largest effect size which the control intervention reliably
191:
The finding of "difference" or "no difference" between two interventions is not a direct demonstration of the internal validity of the trial unless another internal control confirms that the study methods have the ability to show a difference, if one exists, over the range of interest (i.e. the
149:
Lack of assay sensitivity has different implications for trials intended to show a difference greater than zero between interventions (superiority trials) and trials intended to show non-inferiority. Non-inferiority trials attempt to rule out some margin of inferiority between a test and control
183:
or no treatment in past superiority trials. For instance, if there is reliable and reproducible evidence from previous superiority trials of an effect size of 10% for a control intervention compared to placebo, an appropriately designed non-inferiority trial designed to rule out that the test
165:
When two interventions within a trial are shown to have different efficacy (i.e., when one intervention is superior), that finding itself directly demonstrates that the trial had assay sensitivity (assuming the finding is not related to random or systematic error). In contrast, a trial that
192:
trial contains a third group receiving placebo). Since most clinical trials do not contain an internal "negative" control (i.e. a placebo group) to internally validate the trial, the data to evaluate the validity of the trial comes from past trials external to the current trial.
160:
In contrast, if a trial intended to demonstrate efficacy by showing a test intervention is non-inferior to an active control lacks assay sensitivity, the trial may find an ineffective intervention to be non-inferior and could lead to an erroneous conclusion of efficacy.
166:
demonstrates non-inferiority between two interventions, or an unsuccessful superiority trial, generally does not contain such direct evidence of assay sensitivity. However, the idea that non-inferiority trials lack assay sensitivity has been disputed.
450:
425:
157:
lacks assay sensitivity, it will fail to show that the test intervention is superior and will fail to lead to a conclusion of efficacy.
86:
58:
247:
362:
Anderson, JA (2006). "The ethics and science of placebo–controlled trials: Assay sensitivity and the Duhem–Quine thesis".
65:
39:
105:
150:
intervention i.e. rule out that the test intervention is no worse than the control intervention by a chosen amount.
72:
43:
54:
471:
403:
319:
Howick, J (2009). "Questioning the
Methodologic Superiority of 'Placebo' over 'Active' Controlled Trials".
227:
491:
180:
398:
501:
496:
32:
79:
429:
153:
If a trial intended to demonstrate efficacy by showing superiority of a test intervention to
8:
201:
175:
130:
423:
344:
154:
444:
399:"Active Control Non-Inferiority Studies: Theory, Assay Sensitivity, Choice of Margin"
379:
336:
301:
296:
269:
243:
134:
348:
239:
371:
328:
291:
281:
235:
122:
375:
332:
485:
206:
383:
340:
305:
286:
21:
138:
467:
129:
from a less effective or ineffective intervention. Without assay
126:
424:
International
Conference on Harmonization Guidance E-10 (2000).
426:"Choice of Control Group and Related Issues in Clinical Trials"
125:
defined as the ability of a trial to distinguish an effective
476:
274:
Current
Controlled Trials in Cardiovascular Medicine
46:. Unsourced material may be challenged and removed.
483:
396:
169:
225:
449:: CS1 maint: numeric names: authors list (
232:Wiley StatsRef: Statistics Reference Online
179:and reproducibly demonstrates compared to
295:
285:
106:Learn how and when to remove this message
361:
267:
484:
318:
137:and is not capable of comparing the
44:adding citations to reliable sources
15:
13:
364:Journal of Medicine and Philosophy
14:
513:
461:
321:The American Journal of Bioethics
20:
397:Temple, Robert J (2002-02-19).
240:10.1002/9781118445112.stat07119
31:needs additional citations for
417:
390:
355:
312:
261:
226:Chuang-Stein, Christy (2014),
219:
1:
212:
144:
472:National Library of Medicine
404:Food and Drug Administration
7:
234:, American Cancer Society,
195:
10:
518:
170:Differences in sensitivity
376:10.1080/03605310500499203
333:10.1080/15265160903090041
270:"Noninferiority trials"
141:of two interventions.
268:Snapinn, SM (2000).
40:improve this article
287:10.1186/cvm-1-1-019
228:"Assay Sensitivity"
202:Specificity (tests)
121:is a property of a
55:"Assay sensitivity"
468:ClinicalTrials.gov
492:Clinical research
249:978-1-118-44511-2
133:, a trial is not
119:Assay sensitivity
116:
115:
108:
90:
509:
455:
454:
448:
440:
438:
437:
428:. Archived from
421:
415:
414:
412:
411:
394:
388:
387:
359:
353:
352:
316:
310:
309:
299:
289:
265:
259:
258:
257:
256:
223:
135:internally valid
111:
104:
100:
97:
91:
89:
48:
24:
16:
517:
516:
512:
511:
510:
508:
507:
506:
502:Clinical trials
482:
481:
464:
459:
458:
442:
441:
435:
433:
422:
418:
409:
407:
395:
391:
360:
356:
317:
313:
266:
262:
254:
252:
250:
224:
220:
215:
198:
172:
164:
147:
112:
101:
95:
92:
49:
47:
37:
25:
12:
11:
5:
515:
505:
504:
499:
497:Drug discovery
494:
480:
479:
474:
463:
462:External links
460:
457:
456:
416:
389:
354:
311:
260:
248:
217:
216:
214:
211:
210:
209:
204:
197:
194:
171:
168:
146:
143:
123:clinical trial
114:
113:
96:September 2007
28:
26:
19:
9:
6:
4:
3:
2:
514:
503:
500:
498:
495:
493:
490:
489:
487:
478:
475:
473:
469:
466:
465:
452:
446:
432:on 2005-02-16
431:
427:
420:
406:
405:
400:
393:
385:
381:
377:
373:
369:
365:
358:
350:
346:
342:
338:
334:
330:
326:
322:
315:
307:
303:
298:
293:
288:
283:
279:
275:
271:
264:
251:
245:
241:
237:
233:
229:
222:
218:
208:
207:Spectrum bias
205:
203:
200:
199:
193:
189:
185:
182:
177:
167:
162:
158:
156:
151:
142:
140:
136:
132:
128:
124:
120:
110:
107:
99:
88:
85:
81:
78:
74:
71:
67:
64:
60:
57: –
56:
52:
51:Find sources:
45:
41:
35:
34:
29:This article
27:
23:
18:
17:
434:. Retrieved
430:the original
419:
408:. Retrieved
402:
392:
370:(1): 65–81.
367:
363:
357:
327:(9): 34–48.
324:
320:
314:
280:(1): 19–21.
277:
273:
263:
253:, retrieved
231:
221:
190:
186:
173:
163:
159:
152:
148:
118:
117:
102:
93:
83:
76:
69:
62:
50:
38:Please help
33:verification
30:
477:FDA Website
176:sensitivity
131:sensitivity
486:Categories
436:2007-10-21
410:2007-09-16
255:2020-01-21
213:References
145:Importance
66:newspapers
127:treatment
470:from US
445:cite web
384:16464770
349:41559691
341:19998192
306:11714400
196:See also
139:efficacy
181:placebo
155:control
80:scholar
382:
347:
339:
304:
294:
246:
174:Assay
82:
75:
68:
61:
53:
345:S2CID
297:59590
87:JSTOR
73:books
451:link
380:PMID
337:PMID
302:PMID
244:ISBN
59:news
372:doi
329:doi
292:PMC
282:doi
236:doi
42:by
488::
447:}}
443:{{
401:.
378:.
368:31
366:.
343:.
335:.
323:.
300:.
290:.
276:.
272:.
242:,
230:,
453:)
439:.
413:.
386:.
374::
351:.
331::
325:9
308:.
284::
278:1
238::
109:)
103:(
98:)
94:(
84:·
77:·
70:·
63:·
36:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
